BackExelixis Overview
Exelixis Inc

Exelixis Target Price

See Exelixis's analyst price targets ($52) vs the current share price.

Get informed when a big investor buys or sells

+ Follow

Share Price

$56.72

Average Target Price

$52.008.3% downside

11 analysts in the last 4 months

High: $56 | Low: $46

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-08-18BMO Capital$544.8% downsideOpen
2026-08-06Leerink PartnersAndrew Berens$528.3% downsideOpen
2026-08-06Truist FinancialGregory Renza$528.3% downsideOpen
2026-08-03UBS$553% downsideOpen
2026-07-23Morgan StanleySean Laaman$536.6% downsideOpen
2026-07-14BarclaysEtzer Darout$4913.6% downsideOpen
2026-07-13Wells Fargo$4913.6% downsideOpen
2026-07-07RBC Capital$4618.9% downsideOpen
2026-07-02UBSAshwani Verma$528.3% downsideOpen
2026-07-02H.C. WainwrightRobert Burns$561.3% downsideOpen
2026-06-25Truist FinancialGregory Renza$544.8% downsideOpen
2026-04-20Barclays$4520.7% downsideOpen
2026-02-12H.C. Wainwright$544.8% downsideOpen
2026-02-11Stifel Nicolaus$4422.4% downsideOpen
2026-02-04BarclaysEtzer Darout$4422.4% downsideOpen
2026-02-02Morgan StanleySean Laaman$4913.6% downsideOpen
2026-01-14Truist Financial$5110.1% downsideOpen
2026-01-08H.C. WainwrightRobert Burns$528.3% downsideOpen
2026-01-08Morgan Stanley$4815.4% downsideOpen
2026-01-05UBS$4127.7% downsideOpen
2025-11-05H.C. WainwrightRobert Burns$4913.6% downsideOpen
2025-11-05Stifel NicolausStephen Willey$4324.2% downsideOpen
2025-11-05BarclaysEtzer Darout$4127.7% downsideOpen
2025-11-05OppenheimerSilvan Tuerkcan$3636.5% downsideOpen
2025-10-21Morgan Stanley$4422.4% downsideOpen
2025-10-21Leerink Partners$4815.4% downsideOpen
2025-10-21Wells FargoDerek Archila$3047.1% downsideOpen
2025-09-17Morgan Stanley$5011.8% downsideOpen
2025-09-17Goldman Sachs$4717.1% downsideOpen
2025-09-16Barclays$4029.5% downsideOpen
2025-08-12H.C. WainwrightRobert Burns$4618.9% downsideOpen
2025-07-30UBS$3833% downsideOpen
2025-07-15Truist FinancialAsthika Goonewardene$561.3% downsideOpen
2025-07-11UBSAshwani Verma$4324.2% downsideOpen
2025-06-24Jefferies$5011.8% downsideOpen
2025-05-15GuggenheimMichael Schmidt$4520.7% downsideOpen
2025-05-14Morgan StanleySean Laaman$4717.1% downsideOpen
2025-03-13RBC Capital$4029.5% downsideOpen
2025-01-27JMP SecuritiesSilvan Tuerkcan$4127.7% downsideOpen
2025-01-10H.C. WainwrightRobert Burns$4029.5% downsideOpen
2025-01-07GuggenheimMichael Schmidt$4226% downsideOpen
2024-10-30BMO CapitalEtzer Darout$3636.5% downsideOpen
2024-10-30Truist FinancialAsthika Goonewardene$3833% downsideOpen
2024-10-30Piper SandlerJoseph Catanzaro$3636.5% downsideOpen
2024-10-30CitigroupDavid Lebowitz$3833% downsideOpen
2024-10-16Leerink PartnersChristopher Liu$28.549.8% downsideOpen
2024-10-16RBC CapitalKennen MacKay$3440.1% downsideOpen
2024-10-16Goldman SachsChris Shibutani$1868.3% downsideOpen
2024-10-15JefferiesAkash Tewari$3341.8% downsideOpen
2024-10-15Morgan StanleyJeffrey Hung$3047.1% downsideOpen

Exelixis (EXEL) FAQ

Exelixis's target price stands at $52. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

The Street's average target of $52 for EXEL implies 8.3% downside versus today's price ($56.72). Positive implied upside usually reflects optimism on growth or margins, while a large downside can signal valuation or fundamental concerns. Check recommendation mix and recent target changes for more context.

The history chart shows how Exelixis's target price evolved across reporting periods, while the comparison chart places EXEL next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, target price is commonly used to spot outliers. Exelixis's reading of $52 is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.